Subgroup-specific cardiovascular effects of intensive lifestyle intervention: a causal forest analysis in adults with type 2 diabetes and overweight/obesity
Open Access
- 4 July 2026
- journal article
- Published by Springer Nature in Nutrition & Diabetes
- Vol. 16 (1)
Abstract
To evaluate the heterogeneity of treatment effects (HTEs) of intensive lifestyle intervention (ILI) in adults with type 2 diabetes and overweight/obesity, and identify a subgroup with greater cardiovascular benefits from ILI. In a post-hoc analysis of the Look AHEAD trial, causal forest modeling was used to identify HTEs of ILI. The study population was stratified into four subgroups, and the associations of ILI with cardiovascular outcomes were assessed using multivariable Cox modeling compared to diabetes support & education (DSE). Among 4710 participants (mean age 58.9 years, 58.5% women), 768 primary outcomes occurred over a median follow-up of 9.5 years. Key variables identified through causal forest modeling were SF-36 mental health, diabetes duration, and urine albumin-creatinine ratio (ACR). In Subgroup 4 (SF-36 mental health > 55.64 and ACR > 10 mg/g), which had more cardiovascular risk factors and comorbidities, ILI significantly reduced the primary outcome risk (HR: 0.65, 95% CI: 0.48-0.87, P = 0.004) and three secondary outcomes compared to DSE. No cardiovascular benefits were observed in participants with SF-36 mental health ≤ 55.64 or ACR < 10 mg/g. This post-hoc analysis of the Look AHEAD trial showed HTEs of ILI in adults with type 2 diabetes and overweight/obesity. Participants with better mental health, poorer renal function, and more cardiovascular risk factors were more likely to benefit from ILI.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (82370358)
- National Natural Science Foundation of China (82470361)
- National Natural Science Foundation of China (82400495)
This publication has 32 references indexed in Scilit:
- Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart FailureJACC, 2024
- Measuring albuminuria or proteinuria: does one answer fit all?Kidney International, 2023
- Optimal threshold of urinary albumin-to-creatinine ratio (UACR) for predicting long-term cardiovascular and noncardiovascular mortalityInternational Urology and Nephrology, 2023
- Risk of cardiovascular disease, death, and renal progression in diabetes according to albuminuria and estimated glomerular filtration rateDiabetes & Metabolism, 2023
- Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknownKidney International, 2023
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022
- Cardiovascular effects of intensive lifestyle intervention in adults with overweight/obesity and type 2 diabetes according to body weight time in rangeeClinicalMedicine, 2022
- Early life body mass index trajectories and albuminuria in midlife: A 30-year prospective cohort studyeClinicalMedicine, 2022
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or ObesityJAMA, 2021
- Urinary albumin-to-creatinine ratio within normal range and all-cause or cardiovascular mortality among U.S. adults enrolled in the NHANES during 1999–2015Annals of Epidemiology, 2021